PREFERHF: Effects intravenous iron or oral iron therapy compared to placebo in HFpEF with iron deficiency anemia

17 May 2025 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Jose Luis Morales Rull

University Hospital Arnau de Vilanova, Lleida (Spain)

20 More presentations in this session

Presentation thumbnail

DIGITHF: Baseline characteristics compared to recent trials in heart failure with reduced ejection fraction

Professor U. Bavendiek (Hannover, DE)

Presentation thumbnail

Discussant review - DIGITHF

Professor D. van Veldhuisen (Groningen, NL)

Presentation thumbnail

Panel discussion - DIGITHF

Presentation thumbnail

CIRRUSHCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy

Doctor A. Owens (Philadelphia, US)

Presentation thumbnail

Discussant review - CIRRUSHCM

Professor I. Olivotto (Florence, IT)

Access the full session

Session thumbnail

Hottest trials and trial updates (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025

You may be interested in

Congress Presentation

Incorporating iron therapy in heart failure management across the ejection fraction spectrum

Congress Presentation

Iron deficiency in heart failure is associated with worse outcomes across the LVEF spectrum: the role of serum iron in HFpEF

Congress Presentation

Oral iron supplementation with ferric maltol improves iron deficiency anaemia in patients with chronic heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources